25 XP   0   0   10

Cara Therapeutic
Buy, Hold or Sell?

Let's analyse Cara Therapeutic together

PenkeI guess you are interested in Cara Therapeutic. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cara Therapeutic. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cara Therapeutic

I send you an email if I find something interesting about Cara Therapeutic.

Quick analysis of Cara Therapeutic (30 sec.)










What can you expect buying and holding a share of Cara Therapeutic? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.04
Expected worth in 1 year
$-0.82
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.86
Return On Investment
-263.1%

For what price can you sell your share?

Current Price per Share
$0.71
Expected price per share
$0.6 - $0.95
How sure are you?
50%

1. Valuation of Cara Therapeutic (5 min.)




Live pricePrice per Share (EOD)

$0.71

Intrinsic Value Per Share

$-97.06 - $-12.52

Total Value Per Share

$-96.02 - $-11.47

2. Growth of Cara Therapeutic (5 min.)




Is Cara Therapeutic growing?

Current yearPrevious yearGrowGrow %
How rich?$57m$188m-$90.9m-93.7%

How much money is Cara Therapeutic making?

Current yearPrevious yearGrowGrow %
Making money-$29.3m-$20.8m-$8.5m-29.0%
Net Profit Margin-630.8%-425.5%--

How much money comes from the company's main activities?

3. Financial Health of Cara Therapeutic (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#456 / 1009

Most Revenue
#345 / 1009

Most Profit
#784 / 1009

Most Efficient
#764 / 1009

What can you expect buying and holding a share of Cara Therapeutic? (5 min.)

Welcome investor! Cara Therapeutic's management wants to use your money to grow the business. In return you get a share of Cara Therapeutic.

What can you expect buying and holding a share of Cara Therapeutic?

First you should know what it really means to hold a share of Cara Therapeutic. And how you can make/lose money.

Speculation

The Price per Share of Cara Therapeutic is $0.7071. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cara Therapeutic.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cara Therapeutic, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.04. Based on the TTM, the Book Value Change Per Share is $-0.47 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cara Therapeutic.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.59-83.7%-0.54-76.7%-0.39-55.3%-0.36-50.5%-0.28-40.3%
Usd Book Value Change Per Share-0.52-73.9%-0.47-65.8%-0.31-44.5%-0.07-9.9%0.022.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.52-73.9%-0.47-65.8%-0.31-44.5%-0.07-9.9%0.022.9%
Usd Price Per Share0.74-2.54-10.35-12.44-12.83-
Price to Earnings Ratio-0.31--1.22--11.50--17.36--20.00-
Price-to-Total Gains Ratio-1.42--5.76-387.11-70.48-31.79-
Price to Book Ratio0.71-1.29-3.04-4.19-7.36-
Price-to-Total Gains Ratio-1.42--5.76-387.11-70.48-31.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7071
Number of shares1414
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.47-0.07
Usd Total Gains Per Share-0.47-0.07
Gains per Quarter (1414 shares)-657.72-99.01
Gains per Year (1414 shares)-2,630.90-396.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2631-26410-396-406
20-5262-52720-792-802
30-7893-79030-1188-1198
40-10524-105340-1584-1594
50-13154-131650-1980-1990
60-15785-157960-2376-2386
70-18416-184270-2772-2782
80-21047-210580-3168-3178
90-23678-236890-3564-3574
100-26309-263200-3961-3970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%2.043.01.04.3%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%10.030.00.025.0%12.032.02.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%10.030.00.025.0%12.032.02.026.1%

Fundamentals of Cara Therapeutic

About Cara Therapeutic

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Fundamental data was last updated by Penke on 2024-04-11 03:26:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cara Therapeutic.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cara Therapeutic earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • A Net Profit Margin of -1,076.5% means that $-10.76 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cara Therapeutic:

  • The MRQ is -1,076.5%. The company is making a huge loss. -2
  • The TTM is -630.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,076.5%TTM-630.8%-445.7%
TTM-630.8%YOY-425.5%-205.3%
TTM-630.8%5Y-627.7%-3.1%
5Y-627.7%10Y-5,947.1%+5,319.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,076.5%-200.1%-876.4%
TTM-630.8%-216.8%-414.0%
YOY-425.5%-288.3%-137.2%
5Y-627.7%-449.1%-178.6%
10Y-5,947.1%-605.5%-5,341.6%
1.1.2. Return on Assets

Shows how efficient Cara Therapeutic is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • -25.7% Return on Assets means that Cara Therapeutic generated $-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cara Therapeutic:

  • The MRQ is -25.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.7%TTM-22.5%-3.2%
TTM-22.5%YOY-10.2%-12.4%
TTM-22.5%5Y-11.6%-10.9%
5Y-11.6%10Y-12.7%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.7%-13.3%-12.4%
TTM-22.5%-12.8%-9.7%
YOY-10.2%-11.7%+1.5%
5Y-11.6%-13.9%+2.3%
10Y-12.7%-15.7%+3.0%
1.1.3. Return on Equity

Shows how efficient Cara Therapeutic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • -56.6% Return on Equity means Cara Therapeutic generated $-0.57 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cara Therapeutic:

  • The MRQ is -56.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -34.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.6%TTM-34.3%-22.4%
TTM-34.3%YOY-11.5%-22.7%
TTM-34.3%5Y-15.7%-18.6%
5Y-15.7%10Y-16.4%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.6%-16.9%-39.7%
TTM-34.3%-16.1%-18.2%
YOY-11.5%-15.1%+3.6%
5Y-15.7%-19.3%+3.6%
10Y-16.4%-20.2%+3.8%

1.2. Operating Efficiency of Cara Therapeutic.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cara Therapeutic is operating .

  • Measures how much profit Cara Therapeutic makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • An Operating Margin of -1,085.5% means the company generated $-10.85  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cara Therapeutic:

  • The MRQ is -1,085.5%. The company is operating very inefficient. -2
  • The TTM is -644.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,085.5%TTM-644.4%-441.0%
TTM-644.4%YOY-446.3%-198.1%
TTM-644.4%5Y-643.6%-0.8%
5Y-643.6%10Y-6,098.2%+5,454.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,085.5%-296.2%-789.3%
TTM-644.4%-232.5%-411.9%
YOY-446.3%-298.2%-148.1%
5Y-643.6%-492.1%-151.5%
10Y-6,098.2%-632.4%-5,465.8%
1.2.2. Operating Ratio

Measures how efficient Cara Therapeutic is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.85 means that the operating costs are $11.85 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cara Therapeutic:

  • The MRQ is 11.855. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.566. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.855TTM7.566+4.289
TTM7.566YOY5.461+2.105
TTM7.5665Y8.551-0.986
5Y8.55110Y118.167-109.615
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.8553.231+8.624
TTM7.5663.310+4.256
YOY5.4613.890+1.571
5Y8.5515.739+2.812
10Y118.1677.876+110.291

1.3. Liquidity of Cara Therapeutic.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cara Therapeutic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.54 means the company has $4.54 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cara Therapeutic:

  • The MRQ is 4.539. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.597. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.539TTM5.597-1.058
TTM5.597YOY7.611-2.014
TTM5.5975Y6.945-1.348
5Y6.94510Y9.602-2.657
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5393.890+0.649
TTM5.5974.173+1.424
YOY7.6115.344+2.267
5Y6.9456.126+0.819
10Y9.6026.448+3.154
1.3.2. Quick Ratio

Measures if Cara Therapeutic is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • A Quick Ratio of 6.02 means the company can pay off $6.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cara Therapeutic:

  • The MRQ is 6.024. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.821. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.024TTM6.821-0.797
TTM6.821YOY11.834-5.014
TTM6.8215Y10.943-4.122
5Y10.94310Y14.282-3.340
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0243.514+2.510
TTM6.8213.998+2.823
YOY11.8345.380+6.454
5Y10.9436.105+4.838
10Y14.2826.404+7.878

1.4. Solvency of Cara Therapeutic.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cara Therapeutic assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cara Therapeutic to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.55 means that Cara Therapeutic assets are financed with 54.6% credit (debt) and the remaining percentage (100% - 54.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cara Therapeutic:

  • The MRQ is 0.546. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.276. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.546TTM0.276+0.271
TTM0.276YOY0.112+0.163
TTM0.2765Y0.174+0.101
5Y0.17410Y0.159+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5460.339+0.207
TTM0.2760.336-0.060
YOY0.1120.271-0.159
5Y0.1740.366-0.192
10Y0.1590.389-0.230
1.4.2. Debt to Equity Ratio

Measures if Cara Therapeutic is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cara Therapeutic to the Biotechnology industry mean.
  • A Debt to Equity ratio of 120.5% means that company has $1.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cara Therapeutic:

  • The MRQ is 1.205. The company is able to pay all its debts with equity. +1
  • The TTM is 0.477. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.205TTM0.477+0.728
TTM0.477YOY0.127+0.350
TTM0.4775Y0.245+0.231
5Y0.24510Y0.220+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2050.388+0.817
TTM0.4770.402+0.075
YOY0.1270.335-0.208
5Y0.2450.426-0.181
10Y0.2200.461-0.241

2. Market Valuation of Cara Therapeutic

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cara Therapeutic generates.

  • Above 15 is considered overpriced but always compare Cara Therapeutic to the Biotechnology industry mean.
  • A PE ratio of -0.31 means the investor is paying $-0.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cara Therapeutic:

  • The EOD is -0.299. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.314. Based on the earnings, the company is expensive. -2
  • The TTM is -1.219. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.299MRQ-0.314+0.015
MRQ-0.314TTM-1.219+0.905
TTM-1.219YOY-11.500+10.280
TTM-1.2195Y-17.356+16.136
5Y-17.35610Y-19.997+2.641
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.299-2.264+1.965
MRQ-0.314-2.629+2.315
TTM-1.219-2.680+1.461
YOY-11.500-4.145-7.355
5Y-17.356-6.257-11.099
10Y-19.997-6.254-13.743
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cara Therapeutic:

  • The EOD is -0.497. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.523. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.375. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.497MRQ-0.523+0.025
MRQ-0.523TTM-1.375+0.853
TTM-1.375YOY-11.379+10.004
TTM-1.3755Y-13.715+12.339
5Y-13.71510Y-18.167+4.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.497-2.973+2.476
MRQ-0.523-3.333+2.810
TTM-1.375-3.553+2.178
YOY-11.379-5.605-5.774
5Y-13.715-8.376-5.339
10Y-18.167-8.865-9.302
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cara Therapeutic is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.71 means the investor is paying $0.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cara Therapeutic:

  • The EOD is 0.677. Based on the equity, the company is cheap. +2
  • The MRQ is 0.711. Based on the equity, the company is cheap. +2
  • The TTM is 1.292. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.677MRQ0.711-0.034
MRQ0.711TTM1.292-0.581
TTM1.292YOY3.040-1.748
TTM1.2925Y4.190-2.898
5Y4.19010Y7.363-3.173
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6771.896-1.219
MRQ0.7112.115-1.404
TTM1.2922.093-0.801
YOY3.0402.884+0.156
5Y4.1903.542+0.648
10Y7.3633.916+3.447
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cara Therapeutic.

3.1. Institutions holding Cara Therapeutic

Institutions are holding 45.557% of the shares of Cara Therapeutic.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc6.50290.00013554258-153843-4.1488
2023-12-31Vanguard Group Inc4.813802631067326181.2553
2023-12-31Disciplined Growth Investors Inc3.31540.02941812100397032.2401
2023-09-30Chescapmanager LLC3.2140.37617566321010566.104
2023-12-31Farallon Capital Management, L.L.C.2.84730.00571556251-110340-6.6207
2023-09-30Jacobs Levy Equity Management, Inc.2.64210.0144144408842120641.1784
2023-12-31State Street Corporation1.8678010208789560810.333
2023-12-31Geode Capital Management, LLC1.8460.00011008959360983.7105
2023-12-31Federated Hermes Inc1.5220.0015831849283653.5303
2023-12-31AQR Capital Management LLC1.51640.001282879918191128.1209
2023-12-31Renaissance Technologies Corp1.27530.0008697030385130123.4787
2023-12-31Bank of America Corp1.17980.000164481720268345.842
2023-12-31Verition Fund Managegment, LLC1.00630.003255002916000041.0226
2023-12-31Two Sigma Advisers, LLC0.94080.0009514200376800274.2358
2023-12-31Millennium Management LLC0.85480.0002467187-307299-39.6778
2023-12-31Goldman Sachs Group Inc0.7680419744284881211.2373
2023-12-31Northern Trust Corp0.71690.0001391812-25392-6.0862
2023-12-31Acadian Asset Management LLC0.65950.00136047313179857.6355
2023-12-31Stifel Financial Corp0.57280.000331305811663859.3819
2023-12-31Two Sigma Investments LLC0.56220.0005307271237499340.393
Total 38.62410.435521110502+2235120+10.6%

3.2. Funds holding Cara Therapeutic

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.47790.0001135431300
2024-03-28iShares Russell 2000 ETF2.19730.001712009725790.0482
2023-12-31Federated Hermes MDT Small Cap Core IS1.43220.0493782792238363.1406
2023-12-31Federated Hermes MDT SCC Institutional1.43220.0492782792238363.1406
2023-12-31Disciplined Growth - Small Cap Growth1.35350.17267397657397650
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.18150.000564575300
2024-01-31Fidelity Small Cap Index0.82640.00145168000
2024-03-28iShares Russell 2000 Value ETF0.80090.0032437748-278-0.0635
2023-12-14Rize Medical Cannabis & Life Sci ETF0.7363.418440228600
2024-02-29Fidelity Extended Market Index0.48130.0006263069-1275-0.4823
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.42330.000523138600
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.39210.00221431300
2024-02-29Voya Index Plus SmallCap Port I0.36930.074120187100
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.31610.008617276500
2024-03-29Schwab US Small-Cap ETF™0.31420.000917174100
2024-02-29Vanguard Russell 2000 ETF0.30780.0015168229131768.4977
2024-02-29Vanguard Health Care ETF0.30620.00071673558000.4803
2023-12-31Bridgeway Ultra-Small Company Market0.25830.056514120000
2023-12-31NT R2000 Value Index Fund - NL0.22880.0025125063-20833-14.2793
2023-12-31NT R2000 Index Fund - NL0.22720.0013124176-20495-14.1666
Total 16.06253.84528779269+759111+8.6%

3.3. Insider Transactions

Insiders are holding 14.593% of the shares of Cara Therapeutic.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-05Joana GoncalvesSELL27530.83
2024-02-08Christopher PosnerSELL355750.53
2024-02-08Ryan D MaynardSELL54880.53
2024-02-08Scott TerrillionSELL77700.53
2024-02-01Christopher PosnerSELL49810.55
2023-11-02Christopher PosnerSELL37961.22
2023-08-03Christopher PosnerSELL43073.07
2023-06-23Frederique Ph.d. MenzaghiSELL29933.51
2023-06-23Scott TerrillionSELL24833.51
2023-05-05Christopher PosnerSELL38694.4

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cara Therapeutic compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.522-0.465-11%-0.314-40%-0.070-87%0.021-2606%
Book Value Per Share--1.0441.776-41%3.440-70%3.019-65%2.239-53%
Current Ratio--4.5395.597-19%7.611-40%6.945-35%9.602-53%
Debt To Asset Ratio--0.5460.276+98%0.112+387%0.174+213%0.159+243%
Debt To Equity Ratio--1.2050.477+153%0.127+848%0.245+391%0.220+446%
Dividend Per Share----0%-0%-0%-0%
Eps---0.592-0.542-8%-0.391-34%-0.357-40%-0.285-52%
Free Cash Flow Per Share---0.355-0.432+22%-0.360+1%-0.319-10%-0.235-34%
Free Cash Flow To Equity Per Share--0.312-0.252+181%-0.359+215%-0.074+124%0.040+680%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---12.518--------
Intrinsic Value_10Y_min---97.062--------
Intrinsic Value_1Y_max---0.986--------
Intrinsic Value_1Y_min---2.852--------
Intrinsic Value_3Y_max---3.167--------
Intrinsic Value_3Y_min---14.574--------
Intrinsic Value_5Y_max---5.594--------
Intrinsic Value_5Y_min---32.787--------
Market Cap38647540.440-5%40609705.200138868248.300-71%565420458.000-93%680002134.960-94%701006589.480-94%
Net Profit Margin---10.765-6.308-41%-4.255-60%-6.277-42%-59.471+452%
Operating Margin---10.855-6.444-41%-4.463-59%-6.436-41%-60.982+462%
Operating Ratio--11.8557.566+57%5.461+117%8.551+39%118.167-90%
Pb Ratio0.677-5%0.7111.292-45%3.040-77%4.190-83%7.363-90%
Pe Ratio-0.299+5%-0.314-1.219+288%-11.500+3563%-17.356+5428%-19.997+6269%
Price Per Share0.707-5%0.7432.541-71%10.345-93%12.441-94%12.826-94%
Price To Free Cash Flow Ratio-0.497+5%-0.523-1.375+163%-11.379+2077%-13.715+2524%-18.167+3375%
Price To Total Gains Ratio-1.353+5%-1.422-5.764+305%387.110-100%70.480-102%31.786-104%
Quick Ratio--6.0246.821-12%11.834-49%10.943-45%14.282-58%
Return On Assets---0.257-0.225-12%-0.102-60%-0.116-55%-0.127-51%
Return On Equity---0.566-0.343-40%-0.115-80%-0.157-72%-0.164-71%
Total Gains Per Share---0.522-0.465-11%-0.314-40%-0.070-87%0.021-2606%
Usd Book Value--57085000.00097064250.000-41%188034000.000-70%164997750.000-65%122369325.000-53%
Usd Book Value Change Per Share---0.522-0.465-11%-0.314-40%-0.070-87%0.021-2606%
Usd Book Value Per Share--1.0441.776-41%3.440-70%3.019-65%2.239-53%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.592-0.542-8%-0.391-34%-0.357-40%-0.285-52%
Usd Free Cash Flow---19422000.000-23613250.000+22%-19693250.000+1%-17425050.000-10%-12825850.000-34%
Usd Free Cash Flow Per Share---0.355-0.432+22%-0.360+1%-0.319-10%-0.235-34%
Usd Free Cash Flow To Equity Per Share--0.312-0.252+181%-0.359+215%-0.074+124%0.040+680%
Usd Market Cap38647540.440-5%40609705.200138868248.300-71%565420458.000-93%680002134.960-94%701006589.480-94%
Usd Price Per Share0.707-5%0.7432.541-71%10.345-93%12.441-94%12.826-94%
Usd Profit---32337000.000-29382000.000-9%-20853250.000-36%-19367250.000-40%-15479950.000-52%
Usd Revenue--3004000.0005242000.000-43%10466750.000-71%12041550.000-75%6640325.000-55%
Usd Total Gains Per Share---0.522-0.465-11%-0.314-40%-0.070-87%0.021-2606%
 EOD+3 -5MRQTTM+8 -25YOY+7 -265Y+4 -2910Y+7 -26

4.2. Fundamental Score

Let's check the fundamental score of Cara Therapeutic based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.299
Price to Book Ratio (EOD)Between0-10.677
Net Profit Margin (MRQ)Greater than0-10.765
Operating Margin (MRQ)Greater than0-10.855
Quick Ratio (MRQ)Greater than16.024
Current Ratio (MRQ)Greater than14.539
Debt to Asset Ratio (MRQ)Less than10.546
Debt to Equity Ratio (MRQ)Less than11.205
Return on Equity (MRQ)Greater than0.15-0.566
Return on Assets (MRQ)Greater than0.05-0.257
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cara Therapeutic based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.135
Ma 20Greater thanMa 500.797
Ma 50Greater thanMa 1000.818
Ma 100Greater thanMa 2000.780
OpenGreater thanClose0.719
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets125,844
Total Liabilities68,759
Total Stockholder Equity57,085
 As reported
Total Liabilities 68,759
Total Stockholder Equity+ 57,085
Total Assets = 125,844

Assets

Total Assets125,844
Total Current Assets116,158
Long-term Assets9,686
Total Current Assets
Cash And Cash Equivalents 52,183
Short-term Investments 48,983
Net Receivables 4,017
Inventory 2,821
Other Current Assets 8,154
Total Current Assets  (as reported)116,158
Total Current Assets  (calculated)116,158
+/-0
Long-term Assets
Property Plant Equipment 8,186
Other Assets 0
Long-term Assets  (as reported)9,686
Long-term Assets  (calculated)8,186
+/- 1,500

Liabilities & Shareholders' Equity

Total Current Liabilities25,592
Long-term Liabilities43,167
Total Stockholder Equity57,085
Total Current Liabilities
Accounts payable 11,583
Other Current Liabilities 14,009
Total Current Liabilities  (as reported)25,592
Total Current Liabilities  (calculated)25,592
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,088
Long-term Liabilities Other 37,079
Long-term Liabilities  (as reported)43,167
Long-term Liabilities  (calculated)43,167
+/-0
Total Stockholder Equity
Common Stock54
Retained Earnings -684,745
Accumulated Other Comprehensive Income -260
Other Stockholders Equity 742,036
Total Stockholder Equity (as reported)57,085
Total Stockholder Equity (calculated)57,085
+/-0
Other
Capital Stock54
Cash and Short Term Investments 101,166
Common Stock Shares Outstanding 54,478
Liabilities and Stockholders Equity 125,844
Net Debt -9,016
Net Invested Capital 57,085
Net Working Capital 90,566
Property Plant and Equipment Gross 9,853
Short Long Term Debt Total 43,167



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-31
> Total Assets 
10,685
5,537
0
0
22,068
18,083
71,555
68,194
62,372
55,934
51,654
46,441
117,897
110,897
102,013
92,045
80,152
63,828
43,299
117,973
108,047
97,004
80,635
139,893
212,704
190,823
170,587
149,641
263,795
232,959
196,173
168,613
147,136
271,157
250,228
221,454
225,092
247,056
223,866
226,572
213,509
182,237
153,276
134,389
115,338
125,844
125,844115,338134,389153,276182,237213,509226,572223,866247,056225,092221,454250,228271,157147,136168,613196,173232,959263,795149,641170,587190,823212,704139,89380,63597,004108,047117,97343,29963,82880,15292,045102,013110,897117,89746,44151,65455,93462,37268,19471,55518,08322,068005,53710,685
   > Total Current Assets 
0
1,228
0
0
18,347
14,558
68,226
65,055
59,410
53,150
49,057
44,031
115,680
108,934
99,474
89,143
77,018
61,445
41,031
115,805
105,976
95,058
78,813
138,526
211,388
168,139
144,159
124,771
203,462
165,656
132,669
141,915
132,837
195,065
188,351
164,473
171,499
173,290
151,762
176,166
186,780
168,910
142,659
124,736
100,603
116,158
116,158100,603124,736142,659168,910186,780176,166151,762173,290171,499164,473188,351195,065132,837141,915132,669165,656203,462124,771144,159168,139211,388138,52678,81395,058105,976115,80541,03161,44577,01889,14399,474108,934115,68044,03149,05753,15059,41065,05568,22614,55818,347001,2280
       Cash And Cash Equivalents 
4,097
1,117
0
0
17,733
12,357
67,038
62,812
58,393
52,663
47,422
43,191
111,116
15,101
7,922
3,545
5,426
12,092
5,306
9,416
11,792
9,388
11,877
17,802
96,729
15,081
14,188
18,494
34,705
18,305
17,036
56,967
75,281
31,683
22,519
22,335
22,991
13,453
21,362
46,718
42,806
63,741
47,391
58,249
62,875
52,183
52,18362,87558,24947,39163,74142,80646,71821,36213,45322,99122,33522,51931,68375,28156,96717,03618,30534,70518,49414,18815,08196,72917,80211,8779,38811,7929,4165,30612,0925,4263,5457,92215,101111,11643,19147,42252,66358,39362,81267,03812,35717,733001,1174,097
       Short-term Investments 
294
0
0
0
0
0
0
0
0
0
0
0
0
91,640
88,322
81,219
65,994
46,184
31,504
103,020
91,190
83,181
62,644
114,159
109,348
146,302
120,265
96,815
158,384
136,701
103,160
73,218
45,588
149,242
149,063
132,841
121,203
153,582
119,749
110,794
112,806
81,658
66,892
36,442
15,666
48,983
48,98315,66636,44266,89281,658112,806110,794119,749153,582121,203132,841149,063149,24245,58873,218103,160136,701158,38496,815120,265146,302109,348114,15962,64483,18191,190103,02031,50446,18465,99481,21988,32291,640000000000000294
       Net Receivables 
0
31
0
0
58
61
46
537
89
200
215
250
2,593
464
657
981
778
939
1,542
735
802
854
861
589
732
1,590
1,768
1,589
1,817
1,787
1,785
1,606
1,714
2,064
3,751
1,002
21,047
1,152
3,631
9,168
10,771
4,453
7,258
11,241
5,730
4,017
4,0175,73011,2417,2584,45310,7719,1683,6311,15221,0471,0023,7512,0641,7141,6061,7851,7871,8171,5891,7681,5907325898618548027351,5429397789816574642,5932502152008953746615800310
       Inventory 
0
0
0
0
0
34
580
399
0
0
0
509
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,232
0
0
0
0
0
0
0
0
2,584
1,907
3,460
1,835
2,383
3,515
3,420
3,266
2,821
2,8213,2663,4203,5152,3831,8353,4601,9072,584000000008,23200000000000000005090003995803400000
   > Long-term Assets 
0
4,309
0
0
3,721
3,525
3,329
3,139
2,962
2,784
2,597
2,410
2,217
1,963
2,539
2,902
3,134
2,383
2,268
2,168
2,071
1,946
1,822
1,367
1,316
22,684
26,428
24,870
60,333
67,303
63,504
26,698
14,299
76,092
61,877
56,981
53,593
73,766
72,104
50,406
26,729
13,327
10,617
9,653
14,735
9,686
9,68614,7359,65310,61713,32726,72950,40672,10473,76653,59356,98161,87776,09214,29926,69863,50467,30360,33324,87026,42822,6841,3161,3671,8221,9462,0712,1682,2682,3833,1342,9022,5391,9632,2172,4102,5972,7842,9623,1393,3293,5253,721004,3090
       Property Plant Equipment 
5,427
3,609
0
0
3,021
2,825
2,629
2,439
2,262
2,084
1,897
1,710
1,517
1,263
1,070
1,433
1,665
1,614
1,499
1,399
1,302
1,177
1,053
959
908
880
4,333
4,142
3,940
3,736
3,528
3,429
3,385
5,119
4,741
4,357
3,964
3,604
3,240
2,827
2,405
1,977
1,543
1,100
8,488
8,186
8,1868,4881,1001,5431,9772,4052,8273,2403,6043,9644,3574,7415,1193,3853,4293,5283,7363,9404,1424,3338809089591,0531,1771,3021,3991,4991,6141,6651,4331,0701,2631,5171,7101,8972,0842,2622,4392,6292,8253,021003,6095,427
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,396
21,687
20,320
55,985
63,159
59,568
22,861
10,506
70,565
56,728
52,216
49,221
69,754
68,456
47,171
23,916
11,350
9,074
7,053
4,747
0
04,7477,0539,07411,35023,91647,17168,45669,75449,22152,21656,72870,56510,50622,86159,56863,15955,98520,32021,68721,3960000000000000000000000000
       Long-term Assets Other 
0
700
0
0
700
700
700
700
700
700
700
700
700
700
1,469
1,469
1,469
769
769
769
769
769
769
408
408
408
408
408
408
408
408
408
408
408
408
408
408
408
408
408
408
-13,327
-10,617
1,500
1,500
0
01,5001,500-10,617-13,3274084084084084084084084084084084084084084084084084084087697697697697697691,4691,4691,469700700700700700700700700700700007000
> Total Liabilities 
4,581
3,098
0
0
8,477
6,572
6,827
6,626
7,037
4,272
4,230
3,971
4,034
5,853
7,086
9,457
8,350
13,103
14,030
8,753
8,973
10,224
8,532
66,817
63,174
57,193
56,065
50,096
51,901
46,246
35,699
27,685
19,289
22,156
19,769
17,988
17,901
19,534
19,751
22,150
28,689
23,458
16,678
25,457
29,696
68,759
68,75929,69625,45716,67823,45828,68922,15019,75119,53417,90117,98819,76922,15619,28927,68535,69946,24651,90150,09656,06557,19363,17466,8178,53210,2248,9738,75314,03013,1038,3509,4577,0865,8534,0343,9714,2304,2727,0376,6266,8276,5728,477003,0984,581
   > Total Current Liabilities 
2,929
1,686
0
0
7,275
5,433
5,753
5,617
6,093
3,398
3,427
3,239
3,374
5,268
6,089
8,168
6,825
11,533
12,512
7,190
7,272
8,506
6,875
34,823
43,245
40,447
42,405
40,162
48,299
42,894
32,603
24,726
16,598
18,483
16,519
15,170
15,528
17,616
18,296
21,167
28,192
23,458
16,678
25,457
22,881
25,592
25,59222,88125,45716,67823,45828,19221,16718,29617,61615,52815,17016,51918,48316,59824,72632,60342,89448,29940,16242,40540,44743,24534,8236,8758,5067,2727,19012,51211,5336,8258,1686,0895,2683,3743,2393,4273,3986,0935,6175,7535,4337,275001,6862,929
       Short-term Debt 
0
780
0
0
311
0
0
0
0
0
0
0
0
0
0
1,232
998
0
0
0
0
0
0
0
0
0
901
923
945
967
991
1,006
1,030
1,602
1,639
1,677
1,716
1,755
1,795
1,835
1,876
1,918
1,456
982
497
0
04979821,4561,9181,8761,8351,7951,7551,7161,6771,6391,6021,0301,0069919679459239010000000009981,2320000000000311007800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
901
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000090100000000000000000000000000
       Accounts payable 
651
472
0
0
1,288
676
1,586
1,191
1,715
515
938
711
1,263
1,965
2,348
2,931
2,387
4,738
1,688
1,865
1,187
3,829
1,156
3,692
2,638
4,371
4,943
2,485
9,536
9,100
9,309
4,828
6,483
4,893
4,765
3,386
5,369
5,625
5,594
9,740
15,218
9,604
4,424
12,122
7,978
11,583
11,5837,97812,1224,4249,60415,2189,7405,5945,6255,3693,3864,7654,8936,4834,8289,3099,1009,5362,4854,9434,3712,6383,6921,1563,8291,1871,8651,6884,7382,3872,9312,3481,9651,2637119385151,7151,1911,5866761,28800472651
       Other Current Liabilities 
1,525
434
0
0
2,484
1,282
750
1,357
2,434
1,431
1,526
2,439
2,111
3,303
3,741
4,005
3,440
6,795
10,824
5,325
6,085
4,677
5,719
8,861
11,365
9,251
16,734
20,562
22,090
21,130
16,124
18,248
17,148
11,988
10,115
10,107
8,443
10,236
10,907
9,592
11,098
11,936
10,798
24,475
22,384
14,009
14,00922,38424,47510,79811,93611,0989,59210,90710,2368,44310,10710,11511,98817,14818,24816,12421,13022,09020,56216,7349,25111,3658,8615,7194,6776,0855,32510,8246,7953,4404,0053,7413,3032,1112,4391,5261,4312,4341,3577501,2822,484004341,525
   > Long-term Liabilities 
0
1,412
0
0
1,202
1,139
1,074
1,009
944
874
803
732
660
585
997
1,289
1,525
1,570
1,518
1,563
1,701
1,718
1,657
31,994
19,929
16,746
13,660
9,934
3,602
3,352
3,096
2,959
2,691
3,673
3,250
2,818
2,373
1,918
1,455
983
497
11,522
1,456
0
6,815
43,167
43,1676,81501,45611,5224979831,4551,9182,3732,8183,2503,6732,6912,9593,0963,3523,6029,93413,66016,74619,92931,9941,6571,7181,7011,5631,5181,5701,5251,2899975856607328038749441,0091,0741,1391,202001,4120
       Capital Lease Obligations Min Short Term Debt
0
-780
0
0
-311
0
0
0
0
0
0
0
0
0
0
-1,232
-998
0
0
0
0
0
0
0
0
0
4,087
3,849
3,602
3,352
3,096
2,959
2,691
3,673
3,250
2,818
2,373
1,918
1,455
983
497
0
0
0
6,815
6,088
6,0886,8150004979831,4551,9182,3732,8183,2503,6732,6912,9593,0963,3523,6023,8494,087000000000-998-1,2320000000000-31100-7800
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,079
37,079000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
1,074
1,009
944
874
803
732
660
585
997
1,289
1,525
1,570
1,518
1,563
1,701
1,718
1,657
1,695
1,629
1,562
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,5621,6291,6951,6571,7181,7011,5631,5181,5701,5251,2899975856607328038749441,0091,074000000
> Total Stockholder Equity
6,104
2,439
0
0
13,591
11,511
64,728
61,568
55,335
51,662
47,424
42,470
113,863
105,044
94,927
82,588
71,802
50,725
29,269
109,220
99,074
86,780
72,103
73,076
149,530
133,630
114,522
99,545
211,894
186,713
160,474
140,928
127,847
249,001
230,459
203,466
207,191
227,522
204,115
204,422
184,820
158,779
136,598
108,932
85,642
57,085
57,08585,642108,932136,598158,779184,820204,422204,115227,522207,191203,466230,459249,001127,847140,928160,474186,713211,89499,545114,522133,630149,53073,07672,10386,78099,074109,22029,26950,72571,80282,58894,927105,044113,86342,47047,42451,66255,33561,56864,72811,51113,591002,4396,104
   Common Stock
3
3
0
0
17
4
23
23
23
23
23
23
27
27
27
27
27
27
27
33
33
33
33
34
39
39
39
40
46
47
47
47
47
50
50
50
50
53
53
53
53
53
54
54
54
54
545454545353535353505050504747474746403939393433333333272727272727272323232323234170033
   Retained Earnings Total Equity00-624,376-592,897-566,232-535,893-512,713-508,507-480,758-447,376-446,363-415,618-392,317-471,226-454,717-429,649-400,727-372,116-339,274-316,314-294,354-273,702-254,302-237,108-220,341-206,164-193,720-184,420-162,171-140,199-128,657-115,583-104,891-95,361-90,574-84,890-80,201-76,029-69,484-65,839000000
   Accumulated Other Comprehensive Income 
0
-4,626
0
0
-5,218
-5,415
-71,555
-68,194
-62,372
-6,192
-6,192
0
0
-35
4
41
20
3
24
-13
40
-70
-114
-57
13
-114
73
165
153
170
-68
635
363
73
12
-5
1
-358
-1,723
-2,047
-2,148
-1,672
-1,101
-730
-439
-260
-260-439-730-1,101-1,672-2,148-2,047-1,723-3581-51273363635-6817015316573-11413-57-114-7040-1324320414-3500-6,192-6,192-62,372-68,194-71,555-5,415-5,21800-4,6260
   Capital Surplus 
0
0
0
0
0
0
130,544
131,029
131,341
131,840
132,291
133,021
209,197
209,943
210,479
211,177
211,954
212,866
300,151
302,920
305,165
307,158
309,292
327,401
423,180
428,059
430,724
438,614
583,811
587,223
590,144
594,963
598,663
641,195
646,015
649,784
699,482
708,585
714,292
719,129
722,808
726,630
730,542
733,984
0
0
00733,984730,542726,630722,808719,129714,292708,585699,482649,784646,015641,195598,663594,963590,144587,223583,811438,614430,724428,059423,180327,401309,292307,158305,165302,920300,151212,866211,954211,177210,479209,943209,197133,021132,291131,840131,341131,029130,544000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
1,248
0
0
73,937
8,377
130,544
131,029
131,341
131,840
132,291
133,021
209,197
209,943
210,479
211,177
211,954
212,866
213,638
302,920
305,165
307,158
309,292
327,401
423,180
428,059
430,724
438,614
583,811
587,223
590,144
594,963
598,663
641,195
646,015
649,784
654,516
708,585
714,292
719,129
722,808
726,630
730,542
733,984
738,435
742,036
742,036738,435733,984730,542726,630722,808719,129714,292708,585654,516649,784646,015641,195598,663594,963590,144587,223583,811438,614430,724428,059423,180327,401309,292307,158305,165302,920213,638212,866211,954211,177210,479209,943209,197133,021132,291131,840131,341131,029130,5448,37773,937001,2480



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue20,968
Cost of Revenue-6,433
Gross Profit14,53514,535
 
Operating Income (+$)
Gross Profit14,535
Operating Expense-136,030
Operating Income-121,495-121,495
 
Operating Expense (+$)
Research Development108,381
Selling General Administrative27,649
Selling And Marketing Expenses0
Operating Expense136,030136,030
 
Net Interest Income (+$)
Interest Income0
Interest Expense-604
Other Finance Cost-0
Net Interest Income-604
 
Pretax Income (+$)
Operating Income-121,495
Net Interest Income-604
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-118,513-124,477
EBIT - interestExpense = -122,099
-118,513
-117,909
Interest Expense604
Earnings Before Interest and Taxes (EBIT)-121,495-117,909
Earnings Before Interest and Taxes (EBITDA)-121,236
 
After tax Income (+$)
Income Before Tax-118,513
Tax Provision-0
Net Income From Continuing Ops-116,515-118,513
Net Income-118,513
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses142,463
Total Other Income/Expenses Net2,982604
 

Technical Analysis of Cara Therapeutic
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cara Therapeutic. The general trend of Cara Therapeutic is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cara Therapeutic's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cara Therapeutic.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.723 < 0.95 < 0.95.

The bearish price targets are: 0.6311 > 0.6175 > 0.6.

Tweet this
Cara Therapeutic Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cara Therapeutic. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cara Therapeutic Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cara Therapeutic. The current macd is -0.03952097.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cara Therapeutic price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cara Therapeutic. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cara Therapeutic price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cara Therapeutic Daily Moving Average Convergence/Divergence (MACD) ChartCara Therapeutic Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cara Therapeutic. The current adx is 24.02.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cara Therapeutic shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cara Therapeutic Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cara Therapeutic. The current sar is 0.84264608.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cara Therapeutic Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cara Therapeutic. The current rsi is 42.13. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cara Therapeutic Daily Relative Strength Index (RSI) ChartCara Therapeutic Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cara Therapeutic. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cara Therapeutic price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Cara Therapeutic Daily Stochastic Oscillator ChartCara Therapeutic Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cara Therapeutic. The current cci is -81.54190659.

Cara Therapeutic Daily Commodity Channel Index (CCI) ChartCara Therapeutic Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cara Therapeutic. The current cmo is -20.13709238.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cara Therapeutic Daily Chande Momentum Oscillator (CMO) ChartCara Therapeutic Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cara Therapeutic. The current willr is -75.78846766.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cara Therapeutic is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cara Therapeutic Daily Williams %R ChartCara Therapeutic Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cara Therapeutic.

Cara Therapeutic Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cara Therapeutic. The current atr is 0.07850135.

Cara Therapeutic Daily Average True Range (ATR) ChartCara Therapeutic Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cara Therapeutic. The current obv is -42,410,242.

Cara Therapeutic Daily On-Balance Volume (OBV) ChartCara Therapeutic Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cara Therapeutic. The current mfi is 28.63.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cara Therapeutic Daily Money Flow Index (MFI) ChartCara Therapeutic Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cara Therapeutic.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Cara Therapeutic Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cara Therapeutic based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.135
Ma 20Greater thanMa 500.797
Ma 50Greater thanMa 1000.818
Ma 100Greater thanMa 2000.780
OpenGreater thanClose0.719
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cara Therapeutic with someone you think should read this too:
  • Are you bullish or bearish on Cara Therapeutic? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cara Therapeutic? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cara Therapeutic

I send you an email if I find something interesting about Cara Therapeutic.


Comments

How you think about this?

Leave a comment

Stay informed about Cara Therapeutic.

Receive notifications about Cara Therapeutic in your mailbox!